Dendritic cell therapy -
Chronic lymphocytic leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is a mostly slowly progressive disease of the lymphatic system in which dysfunctional B lymphocytes accumulate in the blood, bone marrow, lymph nodes and organs.
The course of the disease can vary greatly – from long stable phases to progressions requiring treatment.
%20IMMUMEDIC%20Limited.jpg)
Classic treatment strategies for CLL
Conventional CLL therapy depends on the stage of the disease, symptoms, genetic risk factors and the general condition of the patients.
Established procedures include:
Watch & Wait (Observing and Waiting)
In cases of early or stable disease progression without relevant symptoms, immediate therapy is often initially omitted.
chemotherapy
Use of classic cytostatic drugs, usually in combination with other active ingredients.
Immunochemotherapy
Combination of chemotherapy and monoclonal antibodies (e.g. against CD20) to target leukemia cells more effectively.
Targeted therapies
Modern drugs such as BTK or BCL-2 inhibitors target specific signaling pathways of leukemia cells and have significantly changed CLL treatment in recent years.
Stem cell transplantation
In selected high-risk cases, an allogeneic stem cell transplant may be considered.
Dendritic cell therapy – an immunological approach to CLL
Dendritic cell therapy is one of the personalized immunological therapy concepts. Its aim is to specifically support the body's own immune system in better recognizing pathologically altered cells.
In this procedure, dendritic cells are extracted from the patient's blood, processed in the laboratory, and loaded with disease-specific antigens. They are then reintroduced into the body to stimulate a targeted immune response.
In CLL, this approach is currently not considered a standard therapy, but rather an adjunctive or experimental immunological strategy. It can be discussed, in particular, within the context of individualized treatment plans, clinical trials, or for immunological support.
Combination therapies and individual concepts
Integrative oncology increasingly explores how conventional therapies, targeted medications, and immunological approaches can be effectively coordinated. The goal is to better individualize therapies, consider side effects, and avoid unnecessarily weakening the immune system.
The suitability of dendritic cell therapy or other immunological procedures always depends on the individual course of the disease, the prior treatments, the immune function and the current therapy situation.
Important NOTE
Dendritic cell therapy does not replace established standard therapies for CLL. Whether and in what form additional immunological approaches may be beneficial should always be determined through individual medical assessment.
Dendritic cell therapy is a patient-specific immunological approach.
No promises of healing are made.